Monopar advances NDA rollout for Wilson disease candidate ALXN1840
Monopar Therapeutics initiated a rolling New Drug Application submission for ALXN1840 to treat Wilson disease. This regulatory advance represents a potential first novel mechanism of action in the US for decades.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day